A multicentre, prospective study of plasma circulating tumour DNA test for detecting RAS mutation in patients with metastatic colorectal cancer
暂无分享,去创建一个
E. Oki | T. Yamanaka | T. Kudo | T. Yoshino | K. Akagi | T. Nishina | Y. Komatsu | T. Denda | Y. Kagawa | H. Bando | Takeshi Kato | Hiroshi Kumamoto
[1] E. Oki,et al. REVERCE: a randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for previously treated metastatic colorectal cancer patients. , 2019 .
[2] F. Rojo,et al. Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer , 2018, British Journal of Cancer.
[3] J. Tabernero,et al. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO–ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[4] J. Tabernero,et al. Incorporating BEAMing technology as a liquid biopsy into clinical practice for the management of colorectal cancer patients: an expert taskforce review , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[5] K. Bramlett,et al. Abstract 739: Orthogonal validation of oncomine cfDNA panel data with digital PCR using TaqMan Rare Mutation Assays , 2017 .
[6] J. Albanell,et al. Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[7] R. Salazar,et al. Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[8] S. Fox,et al. Blood‐based detection of RAS mutations to guide anti‐EGFR therapy in colorectal cancer patients: concordance of results from circulating tumor DNA and tissue‐based RAS testing , 2017, Molecular oncology.
[9] C. Bokemeyer,et al. FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer. , 2015, European journal of cancer.
[10] Sabine Tejpar,et al. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] K. Muro,et al. Clinical Validation of a Multiplex Kit for RAS Mutations in Colorectal Cancer: Results of the RASKET (RAS KEy Testing) Prospective, Multicenter Study , 2015, EBioMedicine.
[12] J. Thiery,et al. Tumour pharmacodynamics and circulating cell free DNA in patients with refractory colorectal carcinoma treated with regorafenib , 2015, Journal of Translational Medicine.
[13] M. Choti,et al. Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies , 2014, Science Translational Medicine.
[14] Enzo Medico,et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer , 2012, Nature.
[15] K. Kinzler,et al. Serial assessment of human tumor burdens in mice by the analysis of circulating DNA. , 2007, Cancer research.